83.18
price up icon2.00%   1.63
 
loading
Metsera Inc stock is traded at $83.18, with a volume of 1.90M. It is up +2.00% in the last 24 hours and up +57.24% over the past month. Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$81.55
Open:
$81.5
24h Volume:
1.90M
Relative Volume:
0.76
Market Cap:
$8.74B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+31.95%
1M Performance:
+57.24%
6M Performance:
+259.46%
1Y Performance:
+0.00%
1-Day Range:
Value
$80.30
$83.86
1-Week Range:
Value
$60.37
$83.86
52-Week Range:
Value
$12.30
$83.86

Metsera Inc Stock (MTSR) Company Profile

Name
Name
Metsera Inc
Name
Phone
(212) 784-6595
Name
Address
3 WORLD TRADE CENTER, NEW YORK
Name
Employee
109
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
MTSR's Discussions on Twitter

Compare MTSR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MTSR
Metsera Inc
83.18 8.58B 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
409.47 105.61B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
657.53 67.99B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
442.70 58.19B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
854.65 52.40B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
189.70 39.60B 447.02M -1.18B -906.14M -6.1812

Metsera Inc Stock (MTSR) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-30-25 Downgrade Wells Fargo Overweight → Equal Weight
Sep-09-25 Initiated Leerink Partners Outperform
Jun-20-25 Initiated Wells Fargo Overweight
Feb-25-25 Initiated BofA Securities Buy
Feb-25-25 Initiated Evercore ISI Outperform
Feb-25-25 Initiated Guggenheim Buy
View All

Metsera Inc Stock (MTSR) Latest News

pulisher
03:22 AM

Novo Nordisk says will not increase its proposal to acquire Metsera, Inc. - MarketScreener

03:22 AM
pulisher
03:19 AM

Novo Nordisk will not increase its proposal to acquire Metsera, Inc. - GlobeNewswire

03:19 AM
pulisher
01:56 AM

Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Benzinga

01:56 AM
pulisher
01:53 AM

Pfizer acquires Metsera in $10 billion deal after competitive bidding with Novo Nordisk - MSN

01:53 AM
pulisher
12:22 PM

Pfizer Sweetens Its Offer for Metsera in Bidding War Against Novo - MSN

12:22 PM
pulisher
12:10 PM

Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports - 1470 & 100.3 WMBD

12:10 PM
pulisher
12:08 PM

Pfizer to Buy Metsera for $10 Billion, Capping Bidding War - Bloomberg.com

12:08 PM
pulisher
Nov 07, 2025

Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle By Reuters - Investing.com

Nov 07, 2025
pulisher
Nov 07, 2025

Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle - Reuters

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer Wins Metsera Bidding War Over Novo With Final $9B Price Tag - BioSpace

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer beats out Novo in bidding war for obesity-drug startup Metsera - statnews.com

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer and Metsera Reach Deal Expected to Top $10 Billion - The Wall Street Journal

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer wins $10bn bidding war for weight-loss start-up Metsera - Financial Times

Nov 07, 2025
pulisher
Nov 07, 2025

Metsera enters merger agreement with Pfizer - StreetInsider

Nov 07, 2025
pulisher
Nov 07, 2025

Metsera says Pfizer to buy Metsera for up to $86.25 per share - MarketScreener

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer - MarketScreener

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer sweetens offer for Metsera in bidding war against Novo - The Edge Malaysia

Nov 07, 2025
pulisher
Nov 07, 2025

Metsera sale could be record size in weight loss universe - PitchBook

Nov 07, 2025
pulisher
Nov 07, 2025

Metsera Enters Merger Agreement With Pfizer - US News Money

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer, Novo risk overpaying in Metsera chase - Axios

Nov 07, 2025
pulisher
Nov 07, 2025

Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy - Benzinga

Nov 07, 2025
pulisher
Nov 07, 2025

Metsera's complex choice between Novo and Pfizer - Axios

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer sues Novo Nordisk and Metsera in bidding war - drugdiscoverytrends.com

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call - Yahoo Finance

Nov 07, 2025
pulisher
Nov 07, 2025

How Metsera Inc. stock performs in stagflation2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com

Nov 07, 2025
pulisher
Nov 07, 2025

Amid Metsera wrestling match, Novo CEO touts 'higher' bid and goads Pfizer - Fierce Biotech

Nov 07, 2025
pulisher
Nov 07, 2025

Is Metsera Inc. stock a safe investment in uncertain marketsMarket Performance Report & Fast Gain Swing Trade Alerts - newser.com

Nov 07, 2025
pulisher
Nov 07, 2025

Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’ - BioSpace

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer and Novo Nordisk’s battle over Metsera - Chemistry World

Nov 07, 2025
pulisher
Nov 07, 2025

Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera - Yahoo Finance

Nov 07, 2025
pulisher
Nov 07, 2025

Metsera weight-loss drug shows "excellent" tolerability in study - medwatch.com

Nov 07, 2025
pulisher
Nov 07, 2025

Rx Rundown: Metsera, Pfizer, Eli Lilly and more - Medical Marketing and Media

Nov 07, 2025
pulisher
Nov 07, 2025

Novo Nordisk, Pfizer make personnel waves as they squabble over Metsera - Endpoints News

Nov 07, 2025
pulisher
Nov 07, 2025

Weight-loss fever inspires epic battle of the pharma giants - The Times

Nov 07, 2025
pulisher
Nov 07, 2025

Why Metsera Inc. stock appeals to analystsBear Alert & Verified Swing Trading Watchlists - newser.com

Nov 07, 2025
pulisher
Nov 07, 2025

How currency fluctuations impact Metsera Inc. stockJuly 2025 News Drivers & Proven Capital Preservation Tips - newser.com

Nov 07, 2025
pulisher
Nov 07, 2025

Novo Locks Horns With Pfizer Over Obesity Startup Metsera - Bloomberg.com

Nov 07, 2025
pulisher
Nov 07, 2025

Historical volatility pattern of Metsera Inc. visualizedWeekly Stock Report & High Accuracy Trade Alerts - newser.com

Nov 07, 2025
pulisher
Nov 07, 2025

This Unlikely Duo Is Developing a Weight-Loss Pill. Big Pharma Is Obsessed. - The Wall Street Journal

Nov 07, 2025
pulisher
Nov 07, 2025

Novo Nordisk CEO challenges Pfizer on Metsera: "Put your hand in your pocket and bid higher" - medwatch.com

Nov 07, 2025
pulisher
Nov 07, 2025

Metsera’s Impressive Clinical Data for Weight-Loss Drug Sparks Bidding War Among Pharma Giants - NAI500

Nov 07, 2025
pulisher
Nov 06, 2025

Novo Nordisk Sweetens Bid for Obesity Drug Startup Metsera - Bloomberg.com

Nov 06, 2025
pulisher
Nov 06, 2025

Metsera's Promising Weight Loss Drug Boosts Stock Amid Acquisiti - GuruFocus

Nov 06, 2025
pulisher
Nov 06, 2025

Novo CEO says its bid for Metsera is higher - 104.1 WIKY

Nov 06, 2025
pulisher
Nov 06, 2025

Pfizer, Novo again raise Metsera bids in intensifying obesity drug battle - Reuters

Nov 06, 2025
pulisher
Nov 06, 2025

Watch Novo CEO Doustdar to Pfizer on Metsera Takeover Battle: ‘Bid Higher’ - Bloomberg.com

Nov 06, 2025
pulisher
Nov 06, 2025

'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera - Investor's Business Daily

Nov 06, 2025
pulisher
Nov 06, 2025

Recon: FTC expresses concern over Novo Nordisk’s desire to buy Metsera; FDA OKs Caplyta as a add-on depression treatment - Regulatory Affairs Professionals Society | RAPS

Nov 06, 2025
pulisher
Nov 06, 2025

Pfizer Matches Novo's $10B Metsera Bid, And Other Rumors - Law360

Nov 06, 2025

Metsera Inc Stock (MTSR) Financials Data

There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$38.56
price down icon 5.44%
$28.66
price down icon 0.62%
$105.98
price up icon 0.70%
$103.14
price down icon 0.20%
biotechnology ONC
$319.97
price down icon 3.73%
$189.70
price up icon 2.17%
Cap:     |  Volume (24h):